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Background: The increased availability of genetic tests for common, complex diseases, such as Alzheimer’s
disease (AD), raises questions about what people are willing to pay for these services. Methods: We studied
willingness-to-pay for genetic testing in a study of AD risk assessment that included APOE genotype disclosure
among 276 first-degree relatives of persons with AD. Results: Seventy-one percent reported that they would ask
for such testing from their doctor if it were covered by health insurance, and 60% would ask for it even if it
required self-pay. Forty-one percent were willing to pay more than $100 for testing, and more than half would
have been willing to pay for the test out of pocket. Participants who learned that they were APOE e4 positive and
those who had higher education were less likely to want testing if covered by insurance, possibly to avoid
discrimination. Conclusion: This is the first report to examine willingness to pay for susceptibility genetic testing
in a sample of participants who had actually undergone such testing. These findings reveal that some partici-
pants find valuable personal utility in genetic risk information even when such information does not have
proven clinical utility.
Introduction
There has recently been an explosion of available ge-netic tests for both monogenic, high-penetrance disorders
and for markers associated with susceptibility to common
complex disorders. Some of these are now available through
direct-to-consumer companies who provide panels of results
for a one-time or subscription fee, and thousands of customers
have purchased these services. However, little is known about
the monetary value that individuals assign to genetic testing,
particularly the value as measured by willingness to pay
(WTP) for such tests.
WTP is a measure used in economic research to evaluate the
potential success or utilization of a program or service and is
defined as the maximum amount of money that an individual
will contribute to equalize a utility change. WTP is also used
to assess the value placed on particular healthcare options,
providing insight into the self-perceived value of a test or
service to an individual in the context of disposable income,
education, and severity of the illness. Open-ended bidding
questions, binary valuation questions, and ordinal scales are
among the several ways to measure WTP.
A small body of literature has examined demographic and
attitudinal factors associated with WTP for tests. For example,
gender, income, risk perception, illness experiences, and
health beliefs have all been found to significantly impact a
person’s willingness to pay for a colorectal screening test (Frew
et al., 2001). Yasunaga et al. (2006) showed that education about
prostate screening did not change willingness to pay for
prostate-specific antigen (PSA) testing, whereas income, age,
and hospitalization history did play a role in WTP. A study
focusing on mammography and ethnicity showed that will-
ingness to pay significantly differed across ethnicities with a
positive family history (Wagner et al., 2001). Caughey et al.
(2004) assessed demand for prenatal diagnostic testing using
willingness to pay as the outcome. They showed that women
older than 35 and those with high income level were more
willing to pay for testing and those who considered them-
selves religious were less likely to pay for prenatal testing.
In the area of Alzheimer’s disease (AD), survey respon-
dents have reported willingness to pay on average between
$120 and $500 for predictive AD testing, depending upon the
accuracy and prior risk conditions of hypothetical scenarios
(Neumann et al., 2001, 2010). However, no studies have asked
individuals about WTP for susceptibility genetic testing after
they have demonstrated their interest and had an opportunity
to value the experience by actually undergoing such testing.
In this article, we build upon the well-documented association
of APOE genotype with risk of AD in which one copy of the e4
allele increases risk by *3-fold and two copies increases risk
by 12–15-fold (Farrer et al., 1997). We examined willingness to
pay for a single genetic test for AD risk, a test that was pro-
vided at no cost in the context of a randomized controlled trial
with healthy, asymptomatic adult children of AD patients.
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Materials and Methods
The Risk Evaluation and Education for AD (REVEAL)
Study is a series of multi-site, randomized, controlled trials
using Apolipoprotein E (APOE) genetic testing for AD risk as a
paradigm for empirically examining the health impact of ge-
netic susceptibility testing for common diseases (Chao et al.,
2008; Green et al., 2009). In the second of these trials, after
receiving their own APOE genotype, participants were asked
scripted questions about what they would be willing to pay
for the APOE genetic testing.
Because study participants were asymptomatic adult chil-
dren of living or deceased individuals with clinically diag-
nosed or autopsy confirmed AD, they already had an
increased risk of AD (Green et al., 2002). A total of 276 subjects
were enrolled from four sites: Boston University, Case Wes-
tern Reserve University, Weill Medical College of Cornell
University, and Howard University. Participants completed
neuropsychological testing before enrollment, and only par-
ticipants without clinically significant cognitive impairment
or levels of anxiety and depression were enrolled. Participants
were assigned to one of two study arms before disclosure. The
Extended Arm involved three visits and *76 min of clinician
time, whereas the Condensed Arm replaced the in-person
education session with a mailed brochure and took *33 min.
Preliminary results of this trial have been reported elsewhere
(Szymaniak et al., 2009). Participants received AD risk infor-
mation based on age, sex, race, family history, and APOE
genotype. Follow-up sessions occurred at 6 weeks, 6 months,
and 1 year postdisclosure.
Questions about patients’ willingness to pay for APOE
genetic testing and the economic value placed on the APOE
genetic test were assessed at the 6-week follow-up with a
mail survey. The WTP questions were as follows: (1) ‘‘If
you could receive the same type of AD risk assessment
from your own doctor’s office.how likely is it that you
would you have asked for this service if health insurance
covered the cost of testing?’’ (willing to have insurance
pay), (2) ‘‘.how likely is it that you would you have asked
for this service if you had to pay for the testing yourself?’’
(willing to self-pay), and (3) ‘‘How much would you be
willing to pay for this AD risk assessment?’’ (payment
scale) (see Appendix A). Answers for the first two questions
were dichotomized as ‘‘willing’’ and ‘‘not willing’’ in the
tables below. The payment scale question was dichoto-
mized based on midpoint cutoffs to compare those willing
to pay more than $100 for testing to those who were not
willing to pay more than $100 for testing.
Age, race, gender, income, education, and baseline per-
ceived risk (percentage) were assessed by self-report. APOE
status was determined by laboratory testing and participants
who had at least one e4 allele were considered to be positive.
Two constructs were measured by asking participants to re-
spond on a 5-point Likert scale, with response choices ranging
from 1 = Strongly disagree to 5 = Strongly agree. ‘‘Desire to
know future AD status’’ was measured by agreement or dis-
agreement to the statement, ‘‘I would like to know if I am
going to develop AD at some point later in my life.’’ ‘‘Concern
about developing AD’’ was measured by agreement or dis-
agreement to the statement, ‘‘I am concerned that I will de-
velop AD someday.’’ Scale values 1, 2, or 3 were considered
‘‘disagree/neutral’’ and scale values 4 or 5 were considered
‘‘agree.’’
We conducted univariate analyses and multivariate logistic
regression to determine factors associated with willingness to
have insurance pay, willingness to self-pay, and willingness
to pay more than $100. Age, gender, race, APOE status, ed-
ucation, income, self-perceived risk, and questions about de-
sire to know risk and concern about developing AD were
evaluated as predictor variables. Statistical analyses used
SAS 9.1.
Results
Demographic characteristics of the 276 subjects were as
follows: mean age was 58.1 (SD 10.6), 70.6% were female,
19.2% were African American, and 96.4% had health in-
surance. Mean number of years of education was 16.1 (SD
2.5) and 73% of participants had incomes ‡ $50,000 per
year. After receiving disclosure of their APOE genotype,
40.6% of subjects learned that they were positive for at least
one e4 allele. Mean baseline perception of risk was 51.1%
(SD 22.5%).
Seventy-one percent of participants reported that they
would request genetic testing for AD if it were covered by
insurance, whereas 60% would ask for it if it were self-pay.
Of note, 29% of participants indicated that they would prob-
ably or definitely not have such testing done in their doctor’s
office if covered by health insurance. A multivariate model
examining predictors of willingness to be tested if insurance
Table 1. Willing to Have Alzheimer’s Disease Risk Assessment If Insurance Pays
Adjusted (multivariable)a
Variable
Willing to be tested
if insurance pays (n = 191)
Not willing to be tested
if insurance pays (n = 78) Odds ratio (95% CI) p-value
Mean age 58.7 – 10.9 56.8 – 9.7 1.023 (0.991, 1.055) 0.1598
Sex (% female) 133 (69.6%) 56 (71.8%) 0.865 (0.429, 1.744) 0.6853
Race (% African American) 40 (20.9%) 10 (12.8%) 2.175 (0.919, 5.150) 0.0772
Mean education, in years 15.8 – 2.7 16.7 – 2.1 0.836 (0.728, 0.961) 0.0118
Income (% ‡ $50K) 129 (72.5%) 55 (74.3%) 1.400 (0.678, 2.874) 0.3633
APOE status (% e4 positive) 67 (35.1%) 43 (55.1%) 0.439 (0.237, 0.812) 0.0087
Baseline self-perceived risk 50.5 – 22.4 53.0 – 23.2 0.998 (0.984, 1.012) 0.7494
Desire to know future AD status 144 (75.8%) 51 (65.4%) 2.364 (1.211, 4.613) 0.0117
Concern about developing AD someday 123 (64.7%) 52 (66.7%) 1.336 (0.665, 2.685) 0.4157
aAdjusted for all the variables in Table 1.
AD, Alzheimer’s disease.
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were paying revealed significant associations with lower
education, greater desire to know future AD status, and
negative APOE e4 status (Table 1). A similar model examin-
ing predictors of willingness to be tested if participants were
required to self-pay revealed significant associations only
with desire to know future AD status and concern about
future risk of AD (Table 2).
In terms of self-pay, 106 participants (41.4%) reported
willingness to pay more than $100 for AD risk assessment
withAPOE disclosure. Of these, 55 (52%) reported willingness
to pay $200, 51 (48%) reported willingness to pay $500 or
more, and 15 (5.8%) reported willingness to pay $1000 or
more. In the multivariate model, higher income and greater
desire to know future AD status were significantly associated
with willingness to self-pay over $100 (Table 3).
Twenty participants (7%) out of the total 276 were missing
values for at least one of the predictor measures, particularly
for income because this variable included ‘‘refuse to answer’’
as a choice. Twenty participants (7%) did not answer the pay
scale question. Seven (2%) did not answer the ‘‘willing to have
AD risk assessment if insurance pays’’ question, and 11 (4%)
did not answer the ‘‘willing to have AD risk assessment if self-
pay’’ question. A comparison of the analyzed and unanalyzed
participants revealed no significant differences between the
groups, except that a slightly larger percentage of participants
included in the analysis indicated that they would like to
know if they would develop AD at some point in their lives
(75% vs. 60%, p= 0.03).
Discussion
This is the first report to examine willingness to pay for
susceptibility gene testing in participants who had actually
undergone such testing. Even though this population was
restricted to first-degree relatives of AD patients who had
volunteered for a study in which they received AD risk as-
sessment and were therefore highly motivated, 71% reported
that they would ask for such testing from their doctor if it
were covered by health insurance, and 60% would ask for it if
it required self-pay. However, 29% of participants probably or
definitely would not want testing in a doctor’s office if health
insurance covered the cost of the test. Participants with higher
education and those who had learned that they were APOE e4
positive were less willing to endorse a scenario wherein in-
surance covered their testing. These patients may be more
aware of the potential negative implications of sharing genetic
information with a health insurance company. Anecdotal
comments from participants suggested that insurance and
employment discrimination were on their minds, and this
interpretation is consistent with other studies of genetic test-
ing. For example, in a study of eligible participants who de-
clined BRCA testing for breast cancer risk, more than half
cited cost concerns and insurance discrimination as the major
reasons for doing so (Peterson et al., 2002).
Predictors for whether or not participants would self-pay
for genetic testing were greater desire to know about such risk
and greater concern about developing AD, suggesting that
Table 2. Willing to Have Alzheimer’s Disease Risk Assessment If Self-Pay
Adjusted (multivariable)a
Variable
Willing to be tested
if self-pay (n = 159)
Not willing to be tested
if self-pay (n = 106) Odds ratio (95% CI) p-value
Mean age 57.7 – 10.0 58.7 – 11.4 1.010 (0.981, 1.040) 0.5065
Sex (% female) 110 (69.2%) 77 (72.6%) 0.864 (0.445, 1.677) 0.6660
Race (% African American) 30 (18.9%) 20 (18.9%) 1.892 (0.869, 4.116) 0.1080
Mean education, in years 16.2 – 2.5 16.0 – 2.6 0.988 (0.877, 1.112) 0.8399
Income (% ‡ $50K) 116 (78.4%) 66 (66%) 1.850 (0.940, 3.639) 0.0748
APOE status (% e4 positive) 61 (38.4%) 46 (43.4%) 0.566 (0.311, 1.029) 0.0621
Baseline Self-Perceived Risk 50.6 – 21.2 52.2 – 24.2 0.993 (0.980, 1.007) 0.3178
Increased desire to know future AD status 128 (81.0%) 66 (62.3%) 3.089 (1.595, 5.980) 0.0008
Increased concern about developing AD someday 113 (71.5%) 57 (53.8%) 3.102 (1.620, 5.940) 0.0006
aAdjusted for all the variables in Table 2.
Table 3. Amount Willing to Pay for Alzheimer’s Disease Risk Assessment
Adjusted (multivariable)a
Variable
Willing to pay > $100
for testing (n = 106)
Willing to pay £ $100
for testing (n = 150) Odds ratio (95% CI) p-value
Mean age 56.9 – 10.4 58.5 – 10.5 1.011 (0.980, 1.043) 0.4864
Sex (% female) 68 (64.2%) 112 (74.7%) 0.702 (0.361, 1.363) 0.2956
Race (% African American) 13 (12.3%) 35 (23.3%) 0.959 (0.424, 2.170) 0.9203
Mean education, in years 16.6 – 2.4 15.8 – 2.5 1.076 (0.949, 1.219) 0.2533
Income (% ‡ $50K) 89 (88.1%) 90 (64.8%) 2.969 (1.367, 6.450) 0.0060
APOE status (% e4 positive) 47 (44.3%) 56 (37.3%) 1.119 (0.619, 2.024) 0.7091
Baseline Self-Perceived Risk 53.0 – 22.3 49.1 – 22.6 1.004 (0.990, 1.018) 0.5567
Increased desire to know future AD status 91 (86.7%) 98 (65.3%) 3.224 (1.516, 6.856) 0.0024
Increased concern about developing AD someday 75 (71.4%) 89 (59.3%) 1.324 (0.681, 2.575) 0.4079
aAdjusted for all the variables in Table 3.
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willingness to self-pay was associated with information
seeking and fear of developing the disease. Over 40% of
participants were willing to pay more than $100 for the APOE
susceptibility test, with a significant proportion willing to pay
$500 or more and 5.8% willing to pay $1000 or more. This is
particularly significant given that personal genome services
currently provide panels of multiple tests within this price
range. Of note, those with negative APOE status were also
willing to pay a greater amount, perhaps because even
probabilistic reassurance is valuable. Those with a strong
desire to find out their chances of developing AD and those
with higher incomes were more likely to pay a higher amount,
and to pay out-of-pocket, for this test.
In this study, all participants had volunteered to receive
APOE genotyping as part of the research study and had ac-
tually received their genotype and risk assessment before they
were queried about willingness to pay. Thus, this represents
an unusually motivated group of individuals. Yet, the study is
distinctive in that all participants underwent a standardized
education protocol about the limits of the susceptibility test-
ing with APOE and the lack of available treatments for AD.
The study therefore examines a situation in which the value of
risk information is addressed, without concern that the par-
ticipants may have misunderstood the predictive accuracy of
the test, or have been misinformed about medical treatments
that could alter their risk of AD. Those participants who en-
dorsed a willingness to pay larger amounts truly valued the
information itself, rather than its potential to improve their
health.
Limitations of our study include small sample size
and homogeneity of subjects in terms of family history, edu-
cation, gender, insurance status, and higher income. Subjects’
WTP was not assessed at baseline, but only after receiv-
ing their APOE results. Subject reports of WTP for services
in our survey may not correlate with actual behavior in
the marketplace. Willingness to pay as a research tool is also
not without controversy, particularly in terms of different
methods of data collection. Some argue that in-person inter-
view is more accurate than a mailed survey (Olsen, 2001).
Another area of debate is whether open-ended questions or a
pay scale format is more effective (Frew et al., 2004). Range
bias can also exist with use of the payment scale (Whynes
et al., 2004). Our study focuses on only one specific disease. It
is not clear whether these results could be generalized to other
diseases.
Why do participants apparently value genetic testing
results that are neither definitive nor actionable? In hypo-
thetical scenarios reported by Neumann et al., subjects re-
ported that their motives included financial planning and
creation of advance directives (Neumann et al., 2001), and
that if faced with positive but untreatable results, they
would both consult with their medical practitioners and
make changes in their personal lives. In prior analyses of
data from the REVEAL Study, we found that participants
cited numerous motivations for seeking APOE testing,
many of which were not related to informing treatment or
prevention. For example, participants stressed planning for
the future and preparing family members for the possibility
of AD (Roberts et al., 2003). In a related study, we found
that e4 + participants were significantly more likely than
their e4- counterparts to report making changes in long-
term care insurance (Zick et al., 2005).
The findings in our study underscore in specific monetary
terms that some participants may find valuable personal
utility in genetic risk information even when such information
does not have proven clinical utility.
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APPENDIX A
1. If you could receive the same type of AD risk assessment
from your own doctor’s office, how likely would you have
asked for this service if:
a..your health insurance covered the cost of testing
Definitely not have testing 1 Same scale used for a and b
Probably not have testing 2
Probably would have testing 3
Definitely would have testing 4
b.you had to pay for the testing yourself
2. How much would you be willing to pay for this AD risk
assessment?
$25 1
$50 2
$100 3
$200 4
$500 5
$1000 6
More than $1000 7
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